COVID-19 jab maker BioNTech said Monday it would build a factory in Singapore that could produce hundreds of millions of doses of vaccines based on its mRNA technology per year in southeast Asia.
For more coronavirus news, visit our dedicated page.
Construction of the manufacturing plant and a regional headquarters in Singapore will start this year, and the site could become operational by 2023, the German company said in a statement.
Pfizer-BioNTech files for full US approval of COVID-19 vaccinePfizer Inc and German partner BioNTech SA have filed for a full approval for their COVID-19 vaccine, which is now authorized only for emergency use, ... Coronavirus
Pfizer, BioNTech apply to extend COVID-19 vaccine use for adolescents in EUPfizer Inc and partner BioNTech SE said on Friday they had applied to the European health regulator to extend the marketing authorization for their ... Coronavirus
BioNTech expects vaccine trial results for babies, other EMA approvals soonBioNTech expects results by September from trials testing the COVID-19 vaccine that it and Pfizer have developed in babies as young as six months old, ... Coronavirus